Search

Your search keyword '"Loré, Karin"' showing total 391 results

Search Constraints

Start Over You searched for: Author "Loré, Karin" Remove constraint Author: "Loré, Karin"
391 results on '"Loré, Karin"'

Search Results

1. Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2

5. Delayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19

7. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses

8. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID

9. Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans

10. Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates

11. NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals

12. Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals

13. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques

14. Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant

15. Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy.

16. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

20. Clonal Tracking of Rhesus Macaque Hematopoiesis Highlights a Distinct Lineage Origin for Natural Killer Cells

21. Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states

23. Progress in vaccine development for infectious diseases—a Keystone Symposia report

25. Cell targeting and immunostimulatory properties of a novel Fcγ-receptor independent agonistic anti-CD40 antibody in rhesus macaques

26. Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial

28. A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses

31. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination

32. Delayed generation of functional virus-specific circulating T follicular helper cells correlates with severe COVID-19

36. Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity

37. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

38. Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination

39. Appearance of IgG to SARS-CoV-2 in saliva effectively indicates seroconversion in mRNA vaccinated immunocompromised individuals

41. Limited access to antigen drives generation of early B cell memory while restraining the plasmablast response

42. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination

44. Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity

48. Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity

Catalog

Books, media, physical & digital resources